DK3174553T3 - Glycokonjugat-vacciner omfattende basisenheder af et molekylekonstrukt, som udtrykker flere integrerede epitoper til formuleringen af en bredspektret vaccine mod infektioner grundet enteropatogene bakterier - Google Patents

Glycokonjugat-vacciner omfattende basisenheder af et molekylekonstrukt, som udtrykker flere integrerede epitoper til formuleringen af en bredspektret vaccine mod infektioner grundet enteropatogene bakterier Download PDF

Info

Publication number
DK3174553T3
DK3174553T3 DK15742232.0T DK15742232T DK3174553T3 DK 3174553 T3 DK3174553 T3 DK 3174553T3 DK 15742232 T DK15742232 T DK 15742232T DK 3174553 T3 DK3174553 T3 DK 3174553T3
Authority
DK
Denmark
Prior art keywords
salmonella
escherichia coli
lps
carbohydrate structures
enterotoxoid
Prior art date
Application number
DK15742232.0T
Other languages
English (en)
Inventor
Massimo Porro
Original Assignee
Biosynth Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynth Srl filed Critical Biosynth Srl
Application granted granted Critical
Publication of DK3174553T3 publication Critical patent/DK3174553T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (21)

1. Antigent multivalent molekylekonstrukt bestående af basisenheder omfattende de hjælper-T-afhængige afgiftede bærerproteiner valgt mellem Enterotoxoid A og Cytotoxoid B fra Clostridium difficile kovalent bundet til et minimum af tre kulhydratstrukturer fra enteropatogene bakterier valgt mellem bakterielle polysaccharider eller afgiftede lipopolysaccharider af forskellig serologisk specificitet, hvor hver kulhydratstruktur omfatter mindst en af de gentagende basisepitoper bestående af et minimum af fem til tolv monosaccharidrester, hvor mindst et mol af bærerprotein er bundet til mindst et mol af hver af de mindst tre kulhydratstrukturer eller deres molære sum.
2. Antigent multivalent molekylekonstrukt ifølge krav 1, hvor nævnte Enterotoxoid A eller Cytotoxoid B stammende fra Clostridium difficile er afgiftede ved formalin-behandling eller ved DNA-rekombinant teknologi.
3. Antigent multivalent molekylekonstrukt ifølge et hvilket som helst af de foregående krav 1-2, hvor nævnte bårne kulhydratstrukturer af forskellig serologisk specificitet er valgt blandt kapsulære polysaccharider af Salmonella typhi, Vibrio cholerae, Escherichia coli og Clostridium difficile eller en kombination deraf.
4. Antigent multivalent molekylekonstrukt ifølge et hvilket som helst af de foregående krav 1-2, hvor nævnte afgiftede lipopolysaccharid er et Endotoxoid.
5. Antigent multivalent molekylekonstrukt ifølge krav 1 eller 4, hvor nævnte bårne kulhydratstrukturer af forskellig serologisk specificitet er valgt blandt afgiftede lipopolysaccharider/Endotoxoider af enteropatogene bakterier valgt blandt Salmonella typhi, Escherichia coli, Vibrio cholerae, Salmonella enteritidis, Shigella flexneri, Salmonella paratyphi A, Salmonella dysenteriae, Shigella sonnei og Salmonella cholerasuis eller en kombination deraf.
6. Antigent multivalent molekylekonstrukt ifølge et hvilket som helst af kravene 1-5, valgt mellem: - Enterotoxoid A kovalent bundet til de kapsulære polysaccharider af Salmonella typhi, Vibrio cholerae og Escherichia coli; - Cytotoxoid B kovalent bundet til de kapsulære polysaccharider af Salmonella typhi, Vibrio cholerae og Escherichia coli; - Enterotoxoid A kovalent bundet til de afgiftede lipopolysaccharider/Endotoxoider af Salmonella enteritidis, Salmonella paratyphi A og Salmonella dysenteriae·, - Cytotoxoid B kovalent bundet til de afgiftede lipopolysaccharider/Endotoxoider af Salmonella enteritidis, Salmonella paratyphi A og Salmonella dysenteriae.
7. Antigent multivalent molekylekonstrukt ifølge et hvilket som helst af de foregående krav, til anvendelse i en vaccine til beskyttelsen af et individ mod infektionerne grundet mindst en af de enteropatogene bakterier valgt fra Clostridium difficile, Salmonella typhi, Escherichia coli, Vibrio cholerae, Salmonella enteritidis, Shigella flexneri, Shigella sonnei, Salmonella paratyphi A, Salmonella dysenteriae, Salmonella cholerasuis eller en kombination deraf.
8. Vaccineformulering omfattende mindst et antigent multivalent molekylekonstrukt som defineret ifølge et hvilket som helst af kravene 1-6 i et fysiologisk acceptabelt vehikel, eventuelt sammen med en adjuvans eller excipienser der er farmaceutisk acceptable.
9. Vaccineformulering ifølge krav 8, hvor dosen af hvert bærerantigen og/eller bårne antigener er i området mellem 0,1 til 100 pg, fortrinsvis fra 1 til 10 pg.
10. Vaccineformulering ifølge et hvilket som helst af kravene 8-9, hvor nævnte adjuvans er valgt mellem en mineraladjuvans valgt fra aluminiumphosphat, aluminiumhydroxid, en organisk adjuvans valgt fra squalene-baserede adjuvanser såsom MF59, QF 21, Addavax og en biologisk adjuvans valgt fra monophosphoryl-lipid A og trehalose dicorynomycolat.
11. Vaccineformulering ifølge et hvilket som helst af kravene 8-10, hvor mængden af adjuvans er i området mellem 0,1-1 mg/dosis, fortrinsvis 0,5 mg/dosis.
12. Vaccineformulering ifølge et hvilket som helst af kravene 8-11, hvor nævnte formulering er egnet til administrationen via subkutan, intramuskulær, intrakutan eller transkutan vej.
13. Bredspektret polyvalent vaccineformulering ifølge et hvilket som helst af de foregående krav 8-12, til anvendelse i human- eller veterinærmedicinsk felt til beskyttelsen af et individ mod de systemiske og enteriske infektioner grundet mindst en af de enteropatogene bakterier valgt blandt Clostridium difficile, Salmonella typhi, Escherichia coli, Vibrio cholerae, Salmonella enteritidis, Shigella flexneri, Shigella sonnei, Salmonella paratyphi A, Salmonella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter eIler en kombination deraf.
14. Bredspektret polyvalent vaccineformulering til anvendelse i human- eller veterinærmedicinsk felt ifølge krav 13, hvor nævnte individ hører til den humane population.
15. Bredspektret polyvalent vaccineformulering til anvendelse i medicinsk felt ifølge krav 14, til anvendelse i forebyggelsen og/eller behandlingen af virale gastrointestinale infektioner grundet humane norovirusser.
16. Konjugationsfremgangsmåde til fremstilling af det antigene multivalente molekylekonstrukt ifølge et hvilket som helst af kravene 1-6, hvilken omfatter de følgende trin: a) kemisk aktivering af de mindst tre antigenisk forskellige kulhydratstrukturer valgt mellem : - kapsulære polysaccharider af Salmonella typhi, Vibrio cholerae, Escherichia coli og Clostridium difficile eller - lipopolysaccharider fra Salmonella typhi, Escherichia coli, Vibrio cholerae, Salmonella enteritidis, Shigella flexneri, Shigella sonnei, Salmonella paratyphi A, Salmonella dysenteriae og Salmonella cholerasuis; til polyfunktionalitet af O-de-hydrogen-afkobling via oxidation og reducerende aminering, som danner imin-reducerede bindinger med en alkyldiamin-spacer, derefter derivatiseret til aktive estere; b) simultan kobling af de mindst tre ester-afledte kulhydratstrukturer til aminogrupperne af det polyfunktionelle bærerprotein Enterotoxoid A eller Cytotoxoid B fra Clostridium difficile, igennem dannelsen af amidbindinger; hvor mindst et mol af bærerprotein reageres med mindst et mol af hver, eller deres molære sum, af nævnte antigenisk forskellige kulhydratstrukturer.
17. Konjugationsfremgangsmåde ifølge krav 16, hvor kulhydratstrukturerne er kemisk aktiveret i deres tilsvarende diaminsmørsyrederivater og de aktive estere er succinimidylestere.
18. Konjugationsfremgangsmåde til fremstilling af det antigene multivalente molekylekonstrukt ifølge et hvilket som helst af kravene 1-6, hvilken omfatter den simultane kobling af aminogrupperne af det polyfunktionelle bærerprotein Enterotoxoid A eller Cytotoxoid B fra Clostridium difficile med mindst tre antigenisk forskellige kulhydratstrukturer valgt mellem: - kapsulære polysaccharider af Salmonella typhi, Vibrio cholera, Escherichia coli og Clostridium difficile eller - lipopolysaccharider fra Salmonella typhi, Escherichia coli, Vibrio cholerae, Salmonella enteritidis, Shigella flexneri, Shigella sonnei, Salmonella paratyphi A, Salmonella dysenteriae og Salmonella cholerasuis-, via reducerende aminering, som danner imin-reducerede bindinger, hvor sådanne kulhydratstrukturer tidligere er aktiveret til polyfunktionalitet, med eller uden molekylespacere, igennem O-de-hydrogen-afkobling i vicinale hydroxylgrupper, via oxidation.
19. Konjugationsfremgangsmåde ifølge et hvilket som helst af kravene 16-18, yderligere omfattende et videre trin til afgiftning af nævnte lipopolysaccharider alternativt ved a) udspaltning af Lipid A-delen før eller efter koblingsreaktionen udføres, eller b) mætning af Lipid A-bindingsstedet igennem en specifik strategi, der bruger syntetiske anti-endotoxin-peptider (SAEP), før eller efter koblingsreaktionen udføres; hvor mindst et mol af bærerprotein reageres med mindst et mol af hver, eller deres molære sum, af nævnte antigenisk forskellige kulhydratstrukturer.
20. Konjugationsfremgangsmåde ifølge et hvilket som helst af kravene 16-19, hvor kulhydratstrukturerne af trin a) omfatter mindst en af de gentagende basisepitoper bestående af et minimum af fem til tolv monosaccharidrester som vurderet ved molekylemassebestemmelse og NMR-spektroskopi, hvor nævnte gentagende basisepitoper antigent bedømmes ved reaktivitet med type-specifikke eller gruppe-specifikke polyklonale eller monoklonale antistoffer igennem bestemmelsen af deres respektive MIC50-værdier i inhibitionen af deres homologe polysaccharid-antistof-referencesystem.
21. Antigent multivalent molekylekonstrukt opnåelig igennem konjugationsfremgangsmåden ifølge et hvilket som helst af kravene 16-20.
DK15742232.0T 2014-07-25 2015-07-24 Glycokonjugat-vacciner omfattende basisenheder af et molekylekonstrukt, som udtrykker flere integrerede epitoper til formuleringen af en bredspektret vaccine mod infektioner grundet enteropatogene bakterier DK3174553T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141361 2014-07-25
PCT/EP2015/066988 WO2016012587A1 (en) 2014-07-25 2015-07-24 Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria

Publications (1)

Publication Number Publication Date
DK3174553T3 true DK3174553T3 (da) 2018-07-23

Family

ID=51494387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15742232.0T DK3174553T3 (da) 2014-07-25 2015-07-24 Glycokonjugat-vacciner omfattende basisenheder af et molekylekonstrukt, som udtrykker flere integrerede epitoper til formuleringen af en bredspektret vaccine mod infektioner grundet enteropatogene bakterier

Country Status (10)

Country Link
US (3) US10500263B2 (da)
EP (1) EP3174553B1 (da)
CN (1) CN106659799B (da)
CA (1) CA2954087C (da)
DK (1) DK3174553T3 (da)
EA (1) EA035556B1 (da)
ES (1) ES2672045T3 (da)
HU (1) HUE038212T2 (da)
SG (1) SG11201700089QA (da)
WO (1) WO2016012587A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2022016587A (es) * 2020-06-18 2023-02-01 Glaxosmithkline Biologicals Sa Bioconjugado tetravalente de shigella (shigella4v).
WO2022216734A1 (en) * 2021-04-06 2022-10-13 The Board Of Trustees Of The University Of Illinois Multivalent cholera multiepitope fusion antigen (mefa) and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US203143A (en) * 1878-04-30 Improvement in embroidering-machines
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
AU781027B2 (en) * 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
AU2002368447A1 (en) * 2002-12-06 2004-06-30 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains ofhaemophilus influenzae and other pathogenic species of gram-negative bacteria
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US7507718B2 (en) 2005-04-11 2009-03-24 Sanofi Pasteur Polymyxin B analogs for LPS detoxification
JP2009521434A (ja) * 2005-12-22 2009-06-04 サノフィ パストゥール インコーポレイテッド 髄膜炎菌由来の誘導体化多糖類−タンパク質の多価コンジュゲートおよびワクチン
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2528648T3 (es) * 2007-09-11 2015-02-11 University Of Guelph Inmunógenos polisacáridos de la Clostridium Difficile
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
BR122019017005B1 (pt) * 2011-04-22 2022-03-29 Wyeth Llc Composições que se relacionam a uma toxina de clostridium difficile mutante
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
EP2554549A1 (en) * 2011-08-02 2013-02-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools
CA3107450A1 (en) * 2012-03-29 2013-10-03 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2014059296A1 (en) * 2012-10-12 2014-04-17 Department Of Veterans Affairs An attenuated ehec and clostridial toxins tcda and tcdb based vaccine for clostridium difficil associated disease (cdad)
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
EP2915347A1 (en) * 2012-11-02 2015-09-09 Telefonaktiebolaget LM Ericsson (PUBL) Methods, a broadcast management unit and a user equipment for handling digital content in a cellular communications network
JP6290918B2 (ja) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN110917220A (zh) * 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
PL404229A1 (pl) * 2013-06-06 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
EP4070815A1 (en) * 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use

Also Published As

Publication number Publication date
US11246919B2 (en) 2022-02-15
EA201692546A1 (ru) 2017-08-31
CN106659799A (zh) 2017-05-10
US20170209563A1 (en) 2017-07-27
SG11201700089QA (en) 2017-02-27
CA2954087C (en) 2023-09-19
HUE038212T2 (hu) 2018-10-29
US11576959B2 (en) 2023-02-14
EP3174553A1 (en) 2017-06-07
ES2672045T3 (es) 2018-06-12
US20200129606A1 (en) 2020-04-30
US10500263B2 (en) 2019-12-10
CN106659799B (zh) 2020-07-17
EP3174553B1 (en) 2018-04-18
EA035556B1 (ru) 2020-07-07
CA2954087A1 (en) 2016-01-28
WO2016012587A1 (en) 2016-01-28
US20210138059A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
US11576959B2 (en) Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
KR101446238B1 (ko) 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법
JP4001625B2 (ja) ２，５−アンヒドロ−ｄ−マンノース末端構造を持つ、抗原性グループｂ連鎖球菌２型および３型多糖断片とその複合ワクチン
US8168195B2 (en) Vaccines against Escherichia coli O157 infection
TR201909110T4 (tr) Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
EP2473188A1 (en) Protein matrix vaccines of improved immunogenicity
Zhang et al. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine
JP5237259B2 (ja) 過剰産生黄色ブドウ球菌株の５型および８型莢膜多糖
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
US20140287476A1 (en) Vibrio cholerae 0139 conjugate vaccines
Grandjean et al. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies
JP2015071630A (ja) ワクチンとして使用される無毒化大腸菌易熱性エンテロトキシン（ｌｔ）との多糖結合
AU767047B2 (en) Vaccines against (escherichia coli) O157 infection
CN1558773A (zh) 由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗
Raso Characterization and immunogenicity of O-Antigen based Shigella Generalized Modules for Membrane Antigens vaccines